Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : PARANOID! TIRED OF TALKING TO YOURSELF? LET'S TALK(TTP) -- Ignore unavailable to you. Want to Upgrade?

To: Lel H who wrote (138)	8/17/1998 10:04:00 AM
From: Scott H. Davis	Respond to of 626

Partially price may reflect absense of news on Iloperidone, but a lot of it is what is going on in the market. The biotech sector as a whole is flat nasty, especialy the smaller, development stage companies. Small caps in general are getting hit - last couple years, seems like whenever there are major market jitters, there is a "flight to quality" herd mentality. Look at AGPH, ISIP, LGND, VICL, XOMA. Just a reminder to look at the context (FBIOX, FBDIX and HQL are also good funds to look at for a sector view) Scott

To: Lel H who wrote (138)	8/17/1998 10:08:00 AM
From: Scott H. Davis	Respond to of 626

Titan Pharmaceuticals Announces Second Quarter Results (Link follows) biz.yahoo.com I'd like to highlight a new item from the release << In addition to the significant progress the Company made in advancing these clinical development programs, Titan is also making substantial progress in other product development programs. The TriGem(tm) product is on target to begin multicenter Phase II clinical trials in small cell lung cancer early next year. Titan also has initiated a Phase II study of TriGem(tm) in psoriasis. This study is based upon an unexpected finding in a melanoma patient, who experienced substantial clearing of long-standing psoriasis after TriGem(tm) administration. Titan subsequently determined that the GD2 antigen, to which TriGem(tm) is directed, was present in psoriatic tissue from this and other patients. The Company filed for patent protection on this approach to psoriasis treatment and has begun a Phase II study to better determine potential efficacy in this disease.>>